These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 28454804)
1. Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. Hess CN; Clare RM; Neely ML; Tricoci P; Mahaffey KW; James SK; Alexander JH; Held C; Lopes RD; Fox KAA; White HD; Wallentin L; Armstrong PW; Harrington RA; Ohman EM; Roe MT Am Heart J; 2017 May; 187():194-203. PubMed ID: 28454804 [TBL] [Abstract][Full Text] [Related]
2. Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. Inohara T; Pieper K; Wojdyla DM; Patel MR; Jones WS; Tricoci P; Mahaffey KW; James SK; Alexander JH; Lopes RD; Wallentin L; Ohman EM; Roe MT; Vemulapalli S Am Heart J; 2018 Jul; 201():25-32. PubMed ID: 29910052 [TBL] [Abstract][Full Text] [Related]
3. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. Elharram M; Sharma A; White W; Bakris G; Rossignol P; Mehta C; Ferreira JP; Zannad F Am Heart J; 2020 Nov; 229():40-51. PubMed ID: 32916607 [TBL] [Abstract][Full Text] [Related]
4. Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. Lopes RD; Leonardi S; Neely B; Neely ML; Ohman EM; Ardissino D; Hamm CW; Goodman SG; Bhatt DL; White HD; Prabhakaran D; Martinez F; Nicolau JC; Winters KJ; Fox KA; Armstrong PW; Roe MT J Am Coll Cardiol; 2016 Mar; 67(11):1289-97. PubMed ID: 26988949 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710 [TBL] [Abstract][Full Text] [Related]
6. Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. Sherwood MW; Lopes RD; Sun JL; Liaw D; Harrington RA; Wallentin L; Laskowitz DT; James SK; Goodman SG; Darius H; Lewis BS; Gibson CM; Pieper KS; Alexander JH Am Heart J; 2018 Mar; 197():1-8. PubMed ID: 29447769 [TBL] [Abstract][Full Text] [Related]
7. Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. Hess PL; Wojdyla DM; Al-Khatib SM; Lokhnygina Y; Wallentin L; Armstrong PW; Roe MT; Ohman EM; Harrington RA; Alexander JH; White HD; Van de Werf F; Piccini JP; Held C; Aylward PE; Moliterno DJ; Mahaffey KW; Tricoci P JAMA Cardiol; 2016 Apr; 1(1):73-9. PubMed ID: 27437658 [TBL] [Abstract][Full Text] [Related]
8. Safety of percutaneous coronary intervention in patients with acute ischemic stroke/transient ischemic attack and acute coronary syndrome. Zeus T; Ketterer U; Leuf D; Dannenberg L; Bönner F; Wagstaff R; Gliem M; Jander S; Kelm M; Polzin A Clin Res Cardiol; 2016 Apr; 105(4):356-63. PubMed ID: 26514353 [TBL] [Abstract][Full Text] [Related]
9. Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives. Yuan Z; Levitan B; Burton P; Poulos C; Brett Hauber A; Berlin JA Curr Med Res Opin; 2014 Sep; 30(9):1733-41. PubMed ID: 24827068 [TBL] [Abstract][Full Text] [Related]
10. Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. Chin CT; Boden WE; Roe MT; Neely B; Neely ML; Leiva-Pons JL; Corbalán R; Gottlieb S; Dalby AJ; Armstrong PW; Prabhakaran D; Fox KA; White HD; Ohman EM; Winters KJ; Schiele F Heart; 2016 Aug; 102(15):1221-9. PubMed ID: 27030601 [TBL] [Abstract][Full Text] [Related]
11. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Armaganijan LV; Alexander KP; Huang Z; Tricoci P; Held C; Van de Werf F; Armstrong PW; Aylward PE; White HD; Moliterno DJ; Wallentin L; Chen E; Harrington RA; Strony J; Mahaffey KW; Lopes RD Am Heart J; 2016 Aug; 178():176-84. PubMed ID: 27502866 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of Post-coronary Dilation to Prevent Recurrent Myocardial Infarction in Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndrome (from the BASE ACS Trial). Karjalainen PP; Niemelä M; Laine M; Airaksinen JK; Ylitalo A; Nammas W Am J Cardiol; 2017 Feb; 119(3):345-350. PubMed ID: 27887689 [TBL] [Abstract][Full Text] [Related]
13. Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome). Fosbøl EL; Ju C; Anstrom KJ; Zettler ME; Messenger JC; Waksman R; Effron MB; Baker BA; Cohen DJ; Peterson ED; Wang TY Circ Cardiovasc Interv; 2016 Nov; 9(11):. PubMed ID: 27789517 [TBL] [Abstract][Full Text] [Related]
14. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Mahaffey KW; Held C; Wojdyla DM; James SK; Katus HA; Husted S; Steg PG; Cannon CP; Becker RC; Storey RF; Khurmi NS; Nicolau JC; Yu CM; Ardissino D; Budaj A; Morais J; Montgomery D; Himmelmann A; Harrington RA; Wallentin L; J Am Coll Cardiol; 2014 Apr; 63(15):1493-9. PubMed ID: 24561148 [TBL] [Abstract][Full Text] [Related]
15. Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study. Guimarães PO; Krishnamoorthy A; Kaltenbach LA; Anstrom KJ; Effron MB; Mark DB; McCollam PL; Davidson-Ray L; Peterson ED; Wang TY JAMA Cardiol; 2017 Jul; 2(7):750-757. PubMed ID: 28538984 [TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509 [TBL] [Abstract][Full Text] [Related]
17. Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). Attar R; Wu A; Wojdyla D; Jensen SE; Andell P; Mahaffey KW; Roe MT; James SK; Wallentin L; Vemulapalli S; Alexander JH; Lopes RD; Ohman EM; Hernandez AF; Patel MR; Jones WS Am J Cardiol; 2022 Sep; 178():11-17. PubMed ID: 35835600 [TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of procedural vs spontaneous myocardial infarction: results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. Bangalore S; Pencina MJ; Kleiman NS; Cohen DJ Am Heart J; 2013 Dec; 166(6):1027-34. PubMed ID: 24268217 [TBL] [Abstract][Full Text] [Related]
20. Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. Roy A; Roe MT; Neely ML; Cyr DD; Zamoryakhin D; Fox KA; White HD; Armstrong PW; Ohman EM; Prabhakaran D Heart; 2015 Feb; 101(4):279-86. PubMed ID: 25538134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]